01—Abstract
Summary
Summary of the 8-K filed October 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release on October 22, 2025 (Exhibit 99.1) reporting results for the three and nine months ended September 30, 2025.
Third-quarter revenue rose 23.7% to $659.9 milliona from $533.3 million, and net new business awards were $789.6 million, up 47.9%, for a net book-to-bill ratio of 1.20x. GAAP net income was $111.1 million, or $3.86 per diluted share, versus $96.4 million, or $3.01 per diluted share, a year earlier. EBITDA increased 24.9% to $148.4 million, with an EBITDA margin of 22.5%.
Backlog as of September 30, 2025 was $3,000.6 millionb, up 2.5% from $2,927.4 million. For the nine months ended September 30, 2025, revenue was $1,821.8 million, up 15.9% on a reported basis, and GAAP net income was $316.0 million, or $10.64 per diluted share. Cash and cash equivalents fell to $285.4 million at September 30, 2025, from $669.4 million at December 31, 2024.
During the nine months, the company repurchased 2,961,924 shares for $912.9 millionc, leaving $821.7 million remaining under its share repurchase program. For full-year 2025, the company forecasts revenue of $2.480 billion to $2.530 billion, GAAP net income of $431.0 million to $439.0 million, GAAP diluted EPS of $14.60 to $14.86, and EBITDA of $545.0 million to $555.0 million. The guidance excludes any share repurchases made after September 30, 2025.
The company will host a conference call on October 23, 2025 at 9:00 a.m. ET.
02—Key points
Key Highlights
- Q3 2025 revenue of $659.9 million, up 23.7% from $533.3 million in Q3 2024; constant-currency revenue growth of 23.4%.
- Net new business awards of $789.6 million in Q3 2025, up 47.9%, producing a net book-to-bill ratio of 1.20x.
- Q3 2025 GAAP diluted EPS of $3.86 versus $3.01 a year earlier; EBITDA of $148.4 million, up 24.9%, with a 22.5% EBITDA margin.
- Backlog of $3,000.6 million at September 30, 2025, up 2.5% from $2,927.4 million a year earlier.
- Cash and cash equivalents of $285.4 million at September 30, 2025, down from $669.4 million at year-end 2024, reflecting $912.9 million of share repurchases in the first nine months.
- Full-year 2025 guidance: revenue of $2.480 billion to $2.530 billion, GAAP net income of $431.0 million to $439.0 million, and EBITDA of $545.0 million to $555.0 million.
- Remaining authorization under the share repurchase program of $821.7 million as of September 30, 2025.
03—Questions
Frequently Asked Questions
How did Medpace perform in the third quarter of 2025?
Revenue rose 23.7% to $659.9 million, GAAP net income was $111.1 million ($3.86 per diluted share), and EBITDA increased 24.9% to $148.4 million. Net new business awards were $789.6 million, giving a net book-to-bill ratio of 1.20x.
What is the company's full-year 2025 outlook?
Medpace forecasts 2025 revenue of $2.480 billion to $2.530 billion, GAAP net income of $431.0 million to $439.0 million, GAAP diluted EPS of $14.60 to $14.86, and EBITDA of $545.0 million to $555.0 million. The guidance excludes share repurchases after September 30, 2025.
How much has Medpace spent on share repurchases?
In the nine months ended September 30, 2025, the company repurchased 2,961,924 shares for a total of $912.9 million, and $821.7 million remained under its authorized program as of September 30, 2025.
How did the company's cash position change in 2025?
Cash and cash equivalents were $285.4 million at September 30, 2025, compared with $669.4 million at December 31, 2024. The company generated $246.2 million in operating cash flow during the third quarter of 2025.
When and where can investors hear more about the results?
Medpace will host a conference call at 9:00 a.m. ET on Thursday, October 23, 2025, with a webcast and replay available in the Investors section of medpace.com, along with a supplemental slide presentation.
04—Continue